{"entity":{"id":"nct03386617","kind":"trial","name":"AKY15-HK-301_NEPA Study","aka":[],"tldr":"A phase 2 trial of Netupitant and palonosetron in Breast cancer, run by Chinese University of Hong Kong, active and no longer recruiting.","summary":"AKY15-HK-301_NEPA Study is a phase 2 interventional study registered as NCT03386617 by Chinese University of Hong Kong, with 55 participants planned, started 2018-02-27 and due to reach its primary completion in 2027-12-31. Interventions recorded: NEPA. Conditions recorded: Breast Cancer.\n\nLinked to the drug Netupitant and palonosetron because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT03386617","url":"https://clinicaltrials.gov/study/NCT03386617"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["netupitant-palonosetron"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03386617","phase":"2","setting":"Open Label Single Arm Study for NEPA [Oral Fixed-dose Combination of 300 mg Netupitant and 0.50 mg Palonosetron] in Hong Kong Oncology Patients Receiving (Neo)-Adjuvant Chemotherapy Treatment Consists of Adriamycin and Cyclophosphamide for Breast Cancer","sponsor":"Chinese University of Hong Kong","enrolled":55,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03386617/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"drug":[{"id":"netupitant-palonosetron","kind":"drug","name":"Netupitant and palonosetron","route":"/drugs/netupitant-palonosetron/"}]}}